1.	Phase III Randomized Study of Radiotherapy With or Without Short-Term Androgen-Deprivation Therapy in Patients With Intermediate-Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0815, RTOG 0815, NCT00936390
2.	Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0924, RTOG-0924, NCT01368588
3.	Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU003-10, NCT01492972
4.	Phase III Study of Dose-Escalated Radiation Therapy and Standard Androgen-Deprivation Therapy (ADT) With a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus Dose-Escalated Radiation Therapy and Enhanced ADT With a LHRH Agonist and Steroid 17alpha-monooxygenase TAK-700 in Patients With High-Risk Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-1115, RTOG-1115, NCT01546987
5.	Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: R04-0092, NCT00138918